HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung
Journal of Clinical Investigation · 01.07.2026 · 136 (13)
DOI: 10.1172/jci198282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 12.05.2026. Verfasst von Headtlove Essel Dadzie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, and. Hauptthemen laut MEDLINE: Hepatocyte Nuclear Factor 4, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Adenocarcinoma, Mucinous. Die Arbeit nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Cellular plasticity is a hallmark of cancer, enabling tumor cells to alter identity and evade therapeutic pressure. In invasive mucinous adenocarcinoma of the lung (IMA), NK2 homeobox 1 (NKX2-1) loss triggers a pulmonary to gastric switch marked by aberrant activation of hepatocyte nuclear factor 4 alpha (HNF4α), a master regulator of gastrointestinal/hepatic differentiation. We show that HNF4α promoted IMA growth and activated a gastric pit cell–like program. Loss of HNF4α enabled forkhead box A1 and A2 (FoxA1/2) transcription factors to bind de novo sites and activate alternative, nongastric identities in IMA. HNF4α also established a mucinous program associated with tolerance to KRAS blockade, and loss of HNF4α enhanced response to KRAS G12D inhibition. Mechanistically, HNF4α blocked cell-cycle exit in drug-tolerant persister cells and promoted activity of the antioxidant transcription factor nuclear factor erythroid 2–related factor 2 (NRF2). NRF2 activation partially rescued the effects of Hnf4a deletion on KRAS G12D inhibition, whereas NRF2 inhibition enhanced sensitivity to KRAS G12D blockade. Thus, HNF4α is a key regulator of growth, identity, and primary response to KRAS G12D inhibition in IMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huntsman Cancer Institute, and.
- Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, USA.
- Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
- Perinatal Institute, Division of Neonatology, Perinatal and Pulmonary Biology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Essel Dadzie, H., Green, Y. S., Camolotto, S. A., Arnold, H. U., Gumbleton, M., Guo, M., Mino-Kenudson, M., Maeda, Y., Spike, B. T., & Snyder, E. L. (2026). HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung. Journal of Clinical Investigation, 136(13). https://doi.org/10.1172/jci198282
Vancouver
Essel Dadzie H, Green YS, Camolotto SA, Arnold HU, Gumbleton M, Guo M, et al. HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung. Journal of Clinical Investigation. 2026;136(13). doi:10.1172/jci198282
BibTeX
@article{EsselDadzie2026,
author = {Essel Dadzie, Headtlove and Green, Yangsook Song and Camolotto, Soledad A and Arnold, Henry U and Gumbleton, Matthew and Guo, Minzhe and Mino-Kenudson, Mari and Maeda, Yutaka and Spike, Benjamin T and Snyder, Eric L},
title = {HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {13},
doi = {10.1172/jci198282}
}
EUVIMED